Fellow's Publications

Recent Graduates/Current Fellows


  1. Piperdi B, Merla A, Perez-Soler R. Targeting Angiogenesis in Squamous Non-Small Cell Lung Cancer. Drugs. 2014; 74: 403-13 PMID:24578213.
  2. Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I, Friedman E, Verma A. Abnormal platelet count is an independent predictor of mortality in the elderly and is influenced by ethnicity. Haematologica. 2014; 9:930-6. PMID: 24510340.
  3. Shcherba M, Liang Y, Fernandes D, Perez-Soler R, Cheng H. Cell cycle inhibitors for the treatment of NSCLC. Expert Opin Pharmacother. 2014; 15:991-1004. PMID: 24666387.
  4. Ng C, Schwartzman L, Moadel R, Haigentz M Jr. Osteopoikilosis: A Benign Condition with the Appearance of Metastatic Bone Disease. J Clin Oncol. 2014; PMID: 24663043.
  5. Tamari R, Schinke C, Bhagat T, Roth M, Braunschweig I, Will B, Steidl U, Verma A. Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone. Leuk Lymphoma. 2014; 55:2901-6. PMID: 24650011.
  6. Pondt C, Rajdev L. Neoadjuvant and Adjuvant Therapy for Gastrointestinal Tumors. J Gastroint Dig Syst 2014, 4:2.
  7. Bachegowda LS, Barta SK. Genetic and molecular targets in lymphoma: implications for prognosis and treatment. Future Oncol. 2014; 10 15:2509-28. PMID: 25525858.
  8. Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R. Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.  Lung Cancer Manag. 2014 3:67-75. PMID: 25342981. 
  9. Konda B, Pathak S, Edwin I, Mishall P, Downie SA, Olson TR, Reed LJ, Friedman EW.   Safe and successful bone marrow biopsy: an anatomical and CT-based cadaver study. Am J Hematol. 2014; 89:943-6. PMID: 24942104.
  10. Shastri A, Shastri SS.Cancer screening and prevention in low-resource settings. Nat Rev Cancer. 2014;14:822-9. PMID: 25355377.
  11. Shcherba M, Liang Y, Fernandes D, Perez-Soler R, Cheng H. Cell cycle inhibitors for the treatment of NSCLC. Expert Opin Pharmacother. 2014; 15:991-1004. PMID: 24666387.
  12. Bachegowda LS, Makower DF, Sparano JA. Taxanes: impact on breast cancer therapy. Anticancer Drugs. 2014; 25:512-21.PMID: 24552749.
  13. Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol. 2014 Oct 15; 6):393-402. PMID:25320655.
  14. Shum H, Rajdev L.  Targeted therapy in advanced gastric cancer: An updated review.  J Cancer Sci 2014; 1:1-13.
  15. Strakhan M, Hurtado-Sbordoni M, Galeas N, Bakirhan K, Alexis K, Elrafei T.  36-year-old female with catastrophic antiphospholipid syndrome treated with eculizumab: a case report and review of literature. Case Rep Hematol. 2014 2014:704371. PMID: 25389502.
  16. Konda B, Bakirhan K, Rajdev L. Systemic treatment of colon cancer. Austin J Med Oncol.2014; 1(2):11.
  17. Chuy J, Konda B, Rajdev L. Current and Emerging Treatment Targets in AdvancedHepatocellular Carcinoma. JSM Clin Oncol Res. 2014; 2: 1039.
  18. Andreopoulou E, Schweber SJ, Sparano JA, McDaid HM.  Therapies for triple negative breast cancer.   Expert Opin Pharmacother. 2015; 16:1-16 PMID: 25881743.
  19. Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R. Emerging drugs for squamous cell lung cancer. Expert Opin Emerg Drugs. 2015; 20:149-60. PMID: 25557559.
  20. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015; 21:24-33. PMID: 25440090.
  21. Augustine TA, Baig M, Sood A, Budagov T, Atzmon G, Mariadason JM, Aparo S, Maitra R, Goel S. Telomere length is a novel predictive biomarker of sensitivity to anti-EGFR therapy in metastatic colorectal cancer. Br J Cancer. 2015: 112:313-8 PMID: 25412235.
  22. Schinke, C, Giricz O, Li W, Shastri A, Gordon S, Barreyro L, Bhagat T, Bhattacharya S, Will B, Steidl U, Verma A. IL-8/CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells, Blood, 2015; 125:3144-52. PMID: 25810490.
  23. Barta SK, Samuel MS, Xue X, Wang D, Lee JY, Mounier N, Ribera JM, Spina M, Tirelli U, Weiss R, Galicier L, Boue F, Little RF, Dunleavy K, Wilson WH, Wyen C, Remick SC, Kaplan LD, Ratner L, Noy A, Sparano JA. Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. Ann Oncol. 2015; 26:958-966. PMID:25632071.
  24. Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H. Emerging treatment for advanced lung cancer with EGFR mutation.Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8. PMID:26153235.
  25. Jou E, Rajdev L. Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol. 2016 May 28; 22(20):4812-23. doi:10.3748/wjg.v22.i20.4812. Review. PMID:27239108
  26. Mantzaris I, Yu Y, Msaouel P, Lam AP, Janakiram M, Friedman EW, Steidl U, Verma AK. Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans. Oncotarget. 2016 Apr 26. doi: 10.18632/oncotarget.8996. [Epub ahead of print] PMID:27144332
  27. Attarian S, Libutti SK, Chuy J..ACTH-Producing Pancreatic Neuroendocrine Tumor Presenting with Severe Hypokalemic Alkalosis: A Case Report. Journal of Gastrointestinal Cancer 2016,  47 (2): 217–220 PMID: 26073616
  28. Gligich O, Guelfguat M. Elderly woman with sharp shoulder pain. J Fam Pract. 2016 65(5):345-347. PMID:27275939.
  29. Jou E, Gligich O, Chan AC, Mohan D, Felsen UR, Ayyappan S, Billett HH, Hui EP, Chan AT, Raghupathy R.. Viral co-infections and paraproteins in HIV: effect on development of hematological malignancies. Ann Hematol. 2016 Mar;95(4):575-80. doi: 10.1007/s00277-016-2588-z. Epub 2016 Jan 9. PMID: 26747296
  30. Jou E, Gligich O, Chan AC, Mohan D, Felsen UR, Ayyappan S, Billett HH, Hui EP, Chan AT, Raghupathy R. Retrospective study of the prevalence and progression of monoclonal gammopathy in HIV positive versus HIV negative patients. Hematol Oncol. 2015 Jul 24. doi: 10.1002/hon.2247. [Epub ahead of print] PMID: 26205037
  31. Shum E, Stuart M, Borczuk A, Wang F, Cheng H, Halmos B. Recent advances in the management of pulmonary sarcomatoid carcinoma.Expert Rev Respir Med. 2016 Mar 10:1-10. [Epub ahead of print] PMID: 26962707
  32. Bakirhan K, Sharma J, Perez-Soler R, Cheng H. Medical Treatment in Elderly Patients with Non-Small Cell Lung Cancer. Curr Treat Options Oncol. 2016 Mar;17(3):13. doi: 10.1007/s11864-016-0388-2. PMID: 26942588.
  33. Toh J, Eisenberg R, Bakirhan K, Verma A, Rubinstein A. Myelodysplastic Syndrome and Acute Lymphocytic Leukemia in Common Variable Immunodeficiency (CVID). J Clin Immunol. 2016 May;36(4):366-9. doi: 10.1007/s10875-016-0269-2. Epub 2016 Mar 18. No abstract available. PMID:26993985.
  34. Park D, Southern W, Calvo M, Kushnir M, Solorzano C, Sinnet M, Billett HH. Treatment with Dalteparin is Associated with a Lower Risk of Bleeding Compared to Treatment with Unfractionated Heparin in Patients with Renal Insufficiency.J Gen Intern Med. 2016 Feb;31(2):182-7. doi: 10.1007/s11606-015-3466-4. Epub 2015 Jul 25. PMID: 26209179.
  35. Merla A, Liu KG, Rajdev L. Targeted Therapy in Biliary Tract Cancers. Curr Treat Options Oncol. 2015 Oct;16(10):48. doi: 10.1007/s11864-015-0366-0. PMID:26266637
  36. Sharma J, Pareek V, Liu H, Cheng H. Emerging treatment for ALK-positive lung cancer. Expert Opin Emerg Drugs. 2016 Jun;21(2):147-55. doi: 10.1080/14728214.2016.1183642. Epub 2016 May 21. PMID: 27122312
  37. Shum E, Halmos B. Skipping the line: bringing MET exon 14 skipping mutations to the forefront of targeted therapy. Transl Cancer Res 2016; 5(2):110-116. doi: 10.21037/tcr.2016.03.12
  38. Prasanna D, Elrafei T, Shum E, Strakhan M. More than a headache: a case of cetuximab-induced aseptic meningitis. BMJ Case Rep 2015. Published online: 12 May 2015. doi:10.1136/bcr-2015-209622.
  39. Diego A. Adrianzen Herrera, Sarah B, Fleisig, Benjamin A. Gartrell: Impressive and durable response to nivolumab in a patient with metastatic type 2 papillary renal cell carcinoma: On-label but without evidence. Invest New Drugs. 2017 May 2. doi: 10.1007/s10637-017-0469-5. PMID:28466375.
  40. Attarian S, Libutti SK, Chuy J: ACTH-Producing Pancreatic Neuroendocrine Tumor Presenting with Severe Hypokalemic Alkalosis: A Case Report. J Gastrointest Cancer. 2016 47:217-20. doi: 10.1007/s12029-015-9740-1. PMID: 26073616.
  41. Castellucci E, He T, Goldstein DY, Halmos B, Chuy J. DNA Polymerase ? Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity. Oncologist. 2017; 22:497-502. doi: 10.1634/theoncologist.2017-0034. Epub 2017 May 2. PMID: 28465371.
  42. Shum E, Wang F, Kim S, Perez-Soler R, Cheng H. Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials. Expert Opin Investig Drugs. 2017; 26:415-426. doi: 10.1080/13543784.2017.1302425. Epub 2017 Mar 9. PMID: 28277882.
  43. Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, Zang X. The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x, and B7-H3. Immunol Rev. 2017 Mar;276(1):26-39. doi: 10.1111/imr.12521. PMID: 28258693.
  44. Janakiram M, Verma A, Wang Y, Budhathoki A, Suarez Londono J, Murakhovskaya I, Braunschweig I, Minniti CP. Accelerated leukemic transformation after haplo-identical transplantation for hydroxyurea-treated sickle cell disease. Leuk Lymphoma. 2017 Jun 7:1-4. doi: 10.1080/10428194.2017.1324158. [Epub ahead of print] PMID: 28587497.
  45. Yue L, Bartenstein M, Zhao W, Ho WT, Han Y, Murdun C, Mailloux AW, Zhang L, Wang X, Budhathoki A, Pradhan K, Rapaport F, Wang H, Shao Z, Ren X, Steidl U, Levine RL, Zhao ZJ, Verma A, Epling-Burnette PK: Efficacy of ALK5 inhibition in myelofibrosis.  JCI Insight. 2017; 2(7): e90932. doi: 10.1172/jci.insight.90932. PMID: 28405618.
  46. Dave M, Khedimi R, Averbukh Y. “Classical Hodgkin’s Lymphoma Presenting with Hemophagocytosis.” MOJ Auto Dis 1(1): 00002.
  47. Birnbaum MR, Ma MW, Fleisig S, Packer S, Amin BD, Jacobson M, McLellan BN. Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma. JAAD Case Rep. 2017 Apr 14;3(3):208-211. doi: 10.1016/j.jdcr.2017.02.015. eCollection 2017 May. PMID: 28443311
  48. Jou E, Gligich O, Chan AC, Mohan D, Felsen UR, Ayyappan S, Billett HH, Hui EP, Chan AT, Raghupathy R. Retrospective study of the prevalence and progression of monoclonal gammopathy in HIV positive versus HIV negative patients.Hematol Oncol. 2017 Mar;35(1):64-68. doi: 10.1002/hon.2247. Epub 2015 Jul 24. PMID: 26205037.
  49. Cumberbatch K, He T, Thorogood Z, Gartrell BA. Emerging drugs for urothelial (bladder) cancer. Expert Opin Emerg Drugs. 2017 Jun;22(2):149-164. doi: 10.1080/14728214.2017.1336536. Epub 2017 Jun 12. PMID: 28556678.
  50. Nandikolla AG, Rajdev L. Ibrutinib-induced severe liver injury. Transl Gastroenterol Hepatol. 2016 Sep 6;1:67. doi: 10.21037/tgh.2016.08.04. eCollection 2016. PMID: 28138633.
  51. Nandikolla AG, Venugopal S, Anampa J. Breast cancer in patients with Li-Fraumeni syndrome - a case-series study and review of literature. Breast Cancer (Dove Med Press). 2017 Mar 23;9:207-215. doi: 10.2147/BCTT.S134241. eCollection 2017.  PMID: 28356770.
  52. Goel S, Negassa A, Khot A, Goyal D, Guo S, Nandikolla A, Bakirhan K, Polineni R, Shah U, Chaudhary I, Ghalib MH, Rajdev L, Kaubisch A, Chuy J, Aparo S. Comparative Effectiveness Research: The Impact of Biologic Agents in Ethnic Minorities With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2017 Mar 14. pii: S1533-0028(16)30187-6. doi: 10.1016/j.clcc.2017.03.004. [Epub ahead of print] PMID: 28412139.
  53. Nandikolla AG, Derman O, Nautsch D, Liu Q, Massoumi H, Venugopal S, Braunschweig I, Janakiram M. Ibrutinib-induced severe liver injury. Clin Case Rep. 2017 Mar 15;5(6):735-738. doi: 10.1002/ccr3.881. eCollection 2017 Jun. PMID: 28588800.
  54. Sharma J, Shum E, Chau V, Paucar D, Cheng H, Halmos B. The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. Respiration. 2017;93(1):1-14. Epub 2016 Nov 29. PMID: 27894113.
  55. Hardin C, Shum E, Singh AP, Perez-Soler R, Cheng H. Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer. Expert Opin Pharmacother. 2017 May;18(7):701-716. doi: 10.1080/14656566.2017.1316374. Epub 2017 Apr 17. PMID: 28388240.
  56. Assal A, Kaner JD, Danda N, Cohen HW, Billett HH. Risk factors and prognosis of ovarian vein thrombosis. Blood Coagul Fibrinolysis. 2017 Feb 3. doi: 10.1097/MBC.0000000000000623. [Epub ahead of print] PMID: 28166111.
  57. Swami U, Shah U, Goel S. Eribulin in non-small cell lung cancer: challenges and potential strategies. Expert Opin Investig Drugs. 2017 Apr;26(4):495-508. doi: 10.1080/13543784.2017.1292250. Epub 2017 Feb 22. Review. PMID: 28161993.
  58. Nandikolla AG, Rajdev L. Targeting angiogenesis in gastrointestinal tumors: current challenges.Transl Gastroenterol Hepatol. 2016 Sep 6;1:67. doi: 10.21037/tgh.2016.08.04. eCollection 2016. Review. PMID: 28138633.
  59. Liu KG, Gupta S, Goel S. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget. 2017 Mar 7;8(10):17313-17327. doi: 10.18632/oncotarget.14388. PMID: 28061473.
  60. Liu KG, Verma A, Derman O, Kornblum N, Janakiram M, Braunschweig I, Battini R. JAK2 V617F mutation, multiple hematologic and non-hematologic processes: an association? Biomark Res. 2016 Oct 19;4:19. eCollection 2016. PMID: 27777768.
  61. Pareek V, Welch M, Ravera E, Zampolin RL, Sequist LV, Halmos B. Marked Differences in CNS Activity among EGFR Inhibitors: Case Report and Mini-Review. J Thorac Oncol. 2016 Nov;11(11):e135-e139. doi: 10.1016/j.jtho.2016.07.010. Epub 2016 Jul 25. No abstract available. PMID: 27464969.
  62. Kushnir M, Cohen HW, Billett HH. Persistent neutrophilia is a marker for an increased risk of venous thrombosis. J Thromb Thrombolysis. 2016 Nov;42(4):545-51. doi: 10.1007/s11239-016-1398-4. PMID: 27383828.
  63. Janakiram M, Pareek V, Cheng H, Narasimhulu DM, Zang X. Immune checkpoint blockade in human cancer therapy: lung cancer and hematologic malignancies. Immunotherapy. 2016 Jun;8(7):809-19. doi: 10.2217/imt-2016-0001. PMID: 27349980.
  64. Shusterman M, Bloomgarden NA, Sotardi ST, Shastri A. Tumor Lysis Syndrome in an Unusual Metastatic Pancreatic Neuroendocrine Tumor with Ectopic ACTH Secretion. J Gastrointest Cancer. 2016 Dec;47(4):423-428. No abstract available. PMID: 26271662.
  65. Targeted Therapy in Lung Cancer. Hardin, C., Cheng, H. Targeted Cancer Therapy. ISBN: 978-1-944685-57-7. SM Group Open Access eBooks.https://www.smgebooks.com/targeted-cancer-therapy/index.php
  66. Stimulation of Adrenergic Activity by Desipramine Enhances Hematopoietic Stem and Progenitor Cell Mobilization along with G-CSF in Multiple Myeloma - A Pilot Study. Shastri A, Budhathoki A, Barta SK, Kornblum N, Derman O, Battini R, Ragupathy R, Verma A, Frenette PS, Braunschweig I, Janakiram M. Am J Hematol. 2017 Jul 4. doi: 10.1002/ajh.24843. PMID: 28675459

Abstracts and Posters

  1. M Shcherba, HD Hosgood, J Lin, D Hanna, UR. Felsen, M Ginsberg, L Fisher, K Wilson, Chung, X Xue, K Anastos, B Piperdi, S Spivack, SM. Keller, HD. Strickler, M Haigentz. Characteristics of HIV+ lung cancer cases in a large clinical population: Implications for lung cancer screening. 2014 ASCO Annual Meeting. Abstract, No:1569.
  2. C Inal, E Yilmaz, H Cheng, C Zhu, J Pullman, RA. Gucalp, SM. Keller, R Perez-Soler, B Piperdi. Effect of reflex testing by pathologists on molecular testing rates in lung cancer patients: Experience from a community-based academic center. 2014 ASCO Annual Meeting. Abstract No: 8098
  3. Tu Y, DL Hershman, CM. Pellegrino, E Andreopoulou, D Makower, S Fineberg, KN.Bhalla, K Kalinsky, K Fehn, M Huang, RK Alpaugh, JA Sparano. Phase I-II study of the histone deacetytase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. 2014 ASCO Annual Meeting, Abstract No: 598.
  4. UH  Shah, AA Khot, D Goyal, S Guo, A Kaubisch, L  Rajdev, S  Goel, S  Aparo. A model of comparative effectiveness research (CER): The impact of biologic agents in a cohort of patients from ethnic minorities with metastatic colorectal cancer (mCRC). 2014 ASCO Annual Meeting Abstract No:e14503.
  5. J Joshi, N  Mounier, X  Xue, D Wang, JM Ribera, C  Wyen, K  Dunleavy, RF Little, WH Wilson, A Noy, JoA Sparano, SK Barta. CNS involvement in patients with AIDS-related lymphomas. 2014 ASCO Annual Meeting Abstract No:8570.
  6. A Sridharan, SA Curtis, JD Kaner, S Aparo, SK. Barta. Hepatitis C co-infection in HIV-positive patients treated for lymphoma. 2014 ASCO Annual Meeting Abstract No:8578.
  7. Lee L, Konda B, Assal A, Zell M, Braunschweig I, Derman O, Kornblum N, Battini R, Verma A, Janakiram M. Plasmablastic lymphoma : A case series of the changing epidemiology of a rare extramedullary plasmacytoid neoplasm, diagnostic challenges and therapeutic implications. Blood 2014 124:2995;
  8. Zell M, Assal A, Konda B, Lee L, Braunschweig I, Derman O, Kornblum N, Battini R, Verma A, Janakiram M. Analysis of large cohort shows that Caribbean Adult T cell leukemia/lymphoma is a chemo refractory disease with very poor prognosis that behaves distinctly from Japanese subtypes. Blood. 2014; 124:1685:
  9. Assal A, Kaner JD, Danda N, Billett HH. Ovarian Vein Thrombosis: Clinical Features, Risk Factors, and Outcomes. Blood 2014 124:587;
  10. Assal A, Medavarapu R, Friedman EW, Yu Y, Verma A, Derman O. Outcomes and Treatment Patterns of Patients with CML in an Inner-City, Underserved, Multi-Ethnic Patient Cohort Reveals Good Overall Survival with Both First and Second Generation TKIs As Initial Therapy. Blood 2014 124:5522;
  11. Shastri A, Schinke C, Varshavsky A, VermaA et all. Targeting of MDS and AML Stem Cells via Inhibition of STAT3 By Pyrimethamine. Blood 2014 124:3602;
  12. Shastri A, Yu Y, Verma A, Barta SK. Sites of Extranodal Involvement Are Prognostic in Patients with Stage I Follicular Lymphoma: An Analysis of the Surveillance, Epidemiology and End Results Database. Blood 2014 124:1670;
  13. Rodgers C, Shastri A, Battini R. Outcome of HCV-Positive Patients with Lymphoma Treated with Rituximab Containing Therapies. Blood 2014 124:1713;
  14. Jou E, Cheung CKM,  Ho RC, Mohan D, Felsen EU, Billett HH, Chan ATC, Hui EP,  Raghupathy R. Retrospective Study of the Incidence and Risk Factors for Hematological Malignancies in Patients with Hepatitis B Virus Infection. Blood 2014 124:5403;
  15. Bachegowda LS, Mantzaris I, Morrone KA, Keshkar N, Li W, Nwankwo G, Shahnaz S, Bhagat TD, Giricz O, Bhattacharrya S, Yu Y,  Schinke CD, Pynadath A, Pellagatti A, Boultwood J, Humphries MJ, Winski SL, Bartenstein M, Guha C, Platanias L, Steidl U, Verma A. Efficacy of Dual Inhibition of p38 Mitogen Activated Protein Kinase (MAPK) and Tie-2 Kinase in Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML). Blood 2014 124:4628.
  16. Mantzaris I, Msaouel P, Lam AP, Friedman EW, Yu Y, Verma A. Ethnicity Specific Cutoffs for Neutropenia Are Predictive of Overall Survival in a Large Elderly Cohort: An Analysis of 26,652 Individuals. Blood 2014 124:4944; 
  17. Bhagat TD, Bartenstein M, Yiting Yu, Marcondes AMQ, Will B, Giricz O, Sohal DP,  Mantzaris I, Wickrema A, Mcmahon C, Cecilia Y, Greally J, Mukherjee S, Steid U, Deeg HC, Verma A. Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors. Blood 2014 124:4379;
  18. Shaker A, Shapira I, Oswald M, Shih A, Mason C, Keogh M, Lee A MicroRNA expression in tissue and plasma of patients with benign cystic ovarian masses and ovarian cancer points to distinct molecular pathways for proliferations and metastases. Poster presentation at the Association for Clinical and Translational Science 2015 meeting, Washington, DC.
  19. Shaker A, Shapira I, Oswald M, Shih A, Mason C, Keogh M, Lee A. Plasma and tissue microRNA patterns are distinct in breast cancer patients relative to healthy controls. Poster presentation at the Association for Clinical and Translational Science 2015 meeting, Washington, DC.
  20. Inal C, Piperdi B, Keller SM, Halmos B, Stoopler M, Limaye SA, Levy BP, Schneider BJ, Kim M, Sides J, Perez-Soler R, Cheng H. Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial). 2015 ASCO meeting, Chicago, IL, May 29-June 2 2015.
  21. Yang Y, Shum H, Haigentz M, Mariuma E, Suhrland M, Maleki S, Acevedo N, Gulko E, Farinhas J, Welch M. “Anti-Ri antibody associated paraneoplastic brainstem and cerebellar dysfunction as the presenting sign of small cell lung carcinoma."  American Academy of Neurology 67th Annual Meeting, April, 2015.
  22. Cheng H, Inal C, Yang Y, Gucalp RA, Haigentz M, Packer SH, Zhu C, Wilson K, Perez-Soler R. EGFR mutation pattern in African American population in a community-based academic center.   J Clin Oncol 33, 2015 (suppl; abstr 8069).
  23. Pendurti G, Shah UH, Swami U, Hou Y, Ghalib MH, Chaudhary I,  Polineni R, Klobocista M, Mukherjee P, Chuy JW, Kaubisch A, Rajdev L, Aparo S, Goel S. Developing a novel prognostic model to predict overall survival (OS) and 90 day mortality rate (90DM) for metastatic colorectal cancer (mCRC) patients in phase I trials. J Clin Oncol 33, 2015 (suppl; abstr e14618).
  24. Kaner JD, Assal A, Sridharan A,  Polineni R, Shastri A, Elias H, Goel S, Janakiram M, Braunschweig I, Verma A. Analysis of a large single center cohort demonstrates poor prognosis of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in HIV infected patients (pts). J Clin Oncol 33, 2015 (suppl; abstr e18077).
  25. Inal C, Piperdi B, Steven M. Keller, Halmosm B, Stoopler M, Limaye S, Levy BP, Schneider BJ, Kim M, Sides J, Perez-Soler R, Cheng H. Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial). J Clin Oncol 33, 2015 (suppl; abstr TPS7584).
  26. Yilmaz E,  Champa D, Di Cristofano A. Synergistic effect of combined PI3K and PLK1 inhibition in anaplastic thyroid carcinoma cells. J Clin Oncol 33, 2015 (suppl; abstr e22205).
  27. Boiles AR, Prasanna D, Shaker AB, Oswald M, Mason C, Keogh M, Lee A, Shapira I. Integrated analysis of miRNAs expression in breast cancer patients to detect genes deregulation involved in malignant transformation.  J Clin Oncol 33, 2015 (suppl; abstr e12560).
  28. Prasanna D, Shaker AB, Boiles AR, Oswald M, Mason C, Keogh M, Lee A, Shapira I. Implications of high expression of miR17-92 cluster in ovarian cancer (OvCa) tissue found in long term survivors.  J Clin Oncol 33, 2015 (suppl; abstr e12561).
  29. Shaker AB, Boiles AR, Prasanna D, Oswald M, Mason C, Keogh M, Lee A, Shapira I.. MiR expression in ovarian cancer (OvCa) and benign ovarian cystic masses (BOM) point to divergent molecular pathways of proliferation and metastasis. J Clin Oncol 33, 2015 (suppl; abstr e16557).
  30. Yilmaz E, Russo MA, Orlacchio A, Forde T, Di Cristofano A. MYC amplification and overexpression in metastatic anaplastic thyroid cancer dictates response to therapy. Poster Presentation at American Association for Cancer Research Annual Meeting (2015) Abs. 2023.
    1. AACR Scholar In-training Award
    2. First prize with oral presentation in New York Head and Neck Society Annual Proffered Paper Session Meeting?
  31. Yuanquan Y, J Sharma, B Halmos, RA Gucalp, M Haigentz, SH Packer, M Keller, C Zhu, R Perez-Soler, H Cheng. Unusual pattern of KRAS mutations in inner city patients with NSCLC. J Clin Oncol 34, 2016 (suppl; abstr e20033)
  32. Jou E, M Shusterman, JW Chuy, A Kaubisch, S Aparo, S Goel. Analysis of survival outcomes among ethnic minorities with pancreatic cancer treated at an urban academic cancer center. J Clin Oncol 34, 2016 (suppl; abstr e15734).
  33. Shum E, B Halmos, H Cheng, R Perez-Soler, R A Gucalp, SH Packer, SM Keller, A Bhargava, Y Eng, E Ravera, C Baker, S Viswanathan, C Na, S Gajavelli, R Browne, M Haigentz. Vinorelbine-induced phlebitis is common in patients receiving adjuvant chemotherapy for non-small cell lung cancer (NSCLC). J Clin Oncol 34, 2016 (suppl; abstr e20016).
  34. V Pareek, JN Sharma, Y Eng, SM Keller, RV Smith, X Guo, CD Shah, LM Gay, JA Elvin, J Suh, JA Vergilio, P Stephens, JS Ross, VA Miller, B Halmos, M Haigentz. Distinguishing head and neck cancer metastasis from second primary squamous lung cancer in the genomic era. J Clin Oncol 34, 2016 (suppl; abstr e17506).
  35. Khan H, J Hall, AA Hakimi, K Pradhan, H Huang, L Cytryn, CP Minniti, A Verma, BA Gartrel. Genomic complexity and prognosis of renal medullary carcinoma. J Clin Oncol 34, 2016 (suppl; abstr 1544).
  36. Khan H, M Grant, N Kim, M Janakiram. Discrepancies in PET-CT for staging bone marrow in HIV positive patients with lymphoma. J Clin Oncol 34, 2016 (suppl; abstr e23126).
  37. Gligich O, Acuna A, Khan H, Kim R, Wang D, Sparano J, Anampa J. Comparison of survival and clinicopathological features between patients Cancer Res February 14 2017 77 (4 Supplement) P2-07-07-P2-07-07; DOI:10.1158/1538-7445.SABCS16-P2-07-07
  38. Acuna A, Gligich O, Khan H, Xue X, Lin J, Sparano J, Anampa J. Time differences in breast cancer diagnosis among minorities in a large referral academic center. Cancer Res March 1 2017 77 (4 Supplement) P5-10-05-P5-10-05; DOI:10.1158/1538-7445.SABCS16-P5-10-05
  39. Justin Kaner, Thibaud S, Sridharan A, Assal A, Polineni R, Zingman B, Sharma A, Elias HK, Weiss L, Janakiram M, Braunschweig I, Goel S, Steidl U, Pradhan K, Shastri A, Will B, Mantzaris I, Chaitowitz M, Verma A.  4345 HIV Is Associated with a High Rate of Unexplained Multilineage Cytopenias and Portends a Poor Prognosis in Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood 2016 128:4345.
  40. Karine Antonovna Darbinyan, Daniel Helbig, Junaid Saleh Esa, Anjali Budhathoki, Swati Goel, Aditi Shastri, Murali Janakiram, Noah Kornblum, Olga Derman, Kira Gritsman, Ulrich Steidl, Amit Verma, Ira Braunschweig, Ioannis Mantzaris. 3600 Hispanic Ethnicity Is Associated with Younger Age at Presentation and Worse Survival in AML. Blood 2016 128:3600;
  41. Jose Nahun Galeas, Nilupa Gaspe, Kith Pradhan, Hernando Cordero, Anjali Budhathoki, Amit Verma, Swati Goel. Anisocytosis Predicts Worse Survival in Secondary Polycythemia.  Blood 2016 128:1254;
  42. Urvi A Shah, B. Hilda Ye, Jeff Hall, Yanhua Wang, Ronald Rice, Rizwan Naeem, Amara Gayathri Nandikolla, Swati Goel, Ioannis Mantzaris, Aditi Shastri, Olga Derman, Noah Kornblum, Ira Braunschweig, Amit Verma, Murali Janakiram.  Genetic Sequencing of Adult T-Cell Leukemia/Lymphoma in the Caribbean Population Shows a Distinct Mutational Profile When Compared to the Japanese Cohort. Blood 2016 128:1758;
  43. Leanne Ostrodka, Michael Samuel, Taneisha Sinclair, Redwan Bhuiyan and Kira Gritsman. PI3 Kinase p110 Delta Is Required for Leukemic Cell Survival and Self-Renewal in t(8;21) Acute Myeloid Leukemia. Blood 2016 128:1553;
  44. Elaine Shum, Huijie Liu, Liang Zhu, Roman Perez Soler,Balazs Halmos,1Haiying Cheng. Synergistic effects of dual inhibition of YAP1 and TAZ in non-small cell lung cancer cells. Proceedings of the 108th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1–5; Washington, DC. Abstract  #518
  45. Daniela De Martino, Emrullah Yilmaz, Arturo Orlacchio, Antonio Di Cristofano. Driver pathway blockage synergizes with PLK1 inhibition in anaplastic thyroid cancer. Proceedings of the 108th Annual Meeting of the American Association for Cancer Research; 2017 Apr 1–5; Washington, DC. Abstract  #1068
  46. Amara Gayathri Nandikolla, Yanhua Wang, Urvi A Shah, Olga Derman, Noah Kornblum, Ioannis Mantzaris, Aditi Shastri, Khan Hina, Kim Nina, Mike Grant, Ira Braunschweig, B. Hilda Ye, Amit Verma, Janakiram Janakiram. Cell of Origin By Immunohistochemistry Is Not Prognostic of Overall Survival in HIV Associated DLBCL- Analysis of Clinical Pathological Markers in HIV DLBCL. Blood 2016 128:1867.
  47. Elaine Shum, Christopher Su, Changcheng Zhu, Rasim A. Gucalp, Missak Haigentz, Stuart H. Packer, Cheryl Baker, Yoko Eng, Elizabeth Ravera, Royston Browne, Roman Perez-Soler, Balazs Halmos, Haiying Cheng. PD-L1 expression profile and immunotherapy (IO) experience in African American (AA) and Hispanic (H) lung cancer (LC) patients: Addressing disparities at a minority-based academic cancer center. J Clin Oncol 35, 2017 (suppl; abstr e18073).
  48. Audrey E. Kam, Imran Chaudhary, Mohammad Haroon Ghalib, Umang H. Shah, Umang Swami, Dennis Yi-Shin Kuo, Caroline Hwang, Tarek N. Elrafei, Bruce Cohen, Benjamin Adam Gartrell, Elizabeth Kaledzi, Jennifer W. Chuy, Haiying Cheng, Lakshmi Rajdev, Missak Haigentz, Sridhar Mani, Sanjay Goel. Risks and benefits of phase I trials: Eighteen-year experience from a single institution. J Clin Oncol 35, 2017 (suppl; abstr e18146)
  49. Shirin Attarian, Murali Janakiram, Ali Ezzati, Rasim A. Gucalp. Dimethyl sulfoxide (DMSO) cryopreserved stem cell infusion-related seizures: A single institution experience. J Clin Oncol 35, 2017 (suppl; abstr e19002).
  50. Santiago Thibaud, Justin D. Kaner, Aditi Shastri, Anjali Budhathoki, Ashwin Sridharan, Swati Goel, Ioannis Mantzaris, Murali Janakiram, Noah Saul Kornblum, Ira Braunschweig, Amit Verma. Chronic hepatitis C as an adverse prognostic factor in myelodysplastic syndromes. J Clin Oncol 35, 2017 (suppl; abstr e18557).